Sifalimumab
Sifalimumab
Sifalimumab (pronounced si-fa-li-mu-mab) is a monoclonal antibody designed for the treatment of autoimmune diseases. It is an experimental drug that was developed by MedImmune, a subsidiary of AstraZeneca.
Etymology
The name "Sifalimumab" is derived from the International Nonproprietary Names (INN), where "si-" refers to the genus Homo (human), "-fali-" is a substem used for immunomodulating monoclonal antibodies, "-mu-" indicates the murine (mouse) origin of the monoclonal antibody, and "-mab" is a suffix for monoclonal antibodies.
Mechanism of Action
Sifalimumab works by targeting and neutralizing interferon alpha, a protein that plays a key role in the immune response. Overproduction of interferon alpha is associated with several autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis.
Clinical Trials
Sifalimumab has undergone Phase II clinical trials for the treatment of systemic lupus erythematosus. However, development was discontinued in 2015 due to lack of efficacy.
Related Terms
- Monoclonal antibody
- Autoimmune disease
- Interferon alpha
- Systemic lupus erythematosus
- Rheumatoid arthritis
External links
- Medical encyclopedia article on Sifalimumab
- Wikipedia's article - Sifalimumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski